Michelle Marcovitz

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

Yelena Y. Janjigian, Eric Van Cutsem, Kei Muro et al. · Future Oncology · 2022 · 133 citations · Full text

Medicine, Oncology, Pharmacology +17

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study

Jyoti Mayadev, Ana T. Nunes, Mary Li et al. · International Journal of Gynecological Cancer · 2020 · 89 citations · Full text

Medicine, Gynecology, Oncology +17

FDA Approval Summary: Selpercatinib for the Treatment of Advanced <i>RET</i> Fusion-Positive Solid Tumors

Elizabeth S. Duke, Diana Bradford, Michelle Marcovitz et al. · Clinical Cancer Research · 2023 · 82 citations · Full text

Medicine, Oncology, Molecular Oncology +13

CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study.

Bradley J. Monk, Jyoti Mayadev, Ana T. Nunes et al. · Journal of Clinical Oncology · 2019 · 11 citations

Medicine, Oncology, Pharmacology +17